Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Equity Ratio (2018 - 2026)

10x Genomics' Equity Ratio history spans 8 years, with the latest figure at 0.76 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 1.08% to 0.76 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.76, a 1.08% decrease, with the full-year FY2025 number at 0.76, down 1.08% from a year prior.
  • Equity Ratio hit 0.76 in Q4 2025 for 10x Genomics, roughly flat from 0.76 in the prior quarter.
  • Over the last five years, Equity Ratio for TXG hit a ceiling of 0.81 in Q3 2021 and a floor of 0.76 in Q3 2025.
  • Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.78 in 2022.
  • Biggest five-year swings in Equity Ratio: rose 19.55% in 2021 and later decreased 3.6% in 2022.
  • Tracing TXG's Equity Ratio over 5 years: stood at 0.8 in 2021, then decreased by 2.42% to 0.78 in 2022, then decreased by 1.95% to 0.77 in 2023, then rose by 0.68% to 0.77 in 2024, then dropped by 1.08% to 0.76 in 2025.
  • Business Quant data shows Equity Ratio for TXG at 0.76 in Q4 2025, 0.76 in Q3 2025, and 0.79 in Q2 2025.